This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Another US femtech startup has joined the race to build up data-sets to support research into and understanding of a range of health issues that can affect women. Decoding the vaginal microbiome is thus seen as an opportunity to support a broad range of women’s health goals.
Developing new packaged foods and consumer goods can take a couple years as companies research, prototype and test products. The present and future of food tech investment opportunity. It also identifies “white space opportunities,” or situations where there is unmet demand.
You’d think data visualization and exploration is a bit of a solved problem thanks to the likes of Tableau, Sisense, Looker, Microsoft Power BI and their competitors. But for the most part, these tools were developed before every company had a data lake and warehouse — let alone a lakehouse.
” This is emerging as a very big opportunity in complex fields like oncology: cancer mutates and behaves differently depending on many factors, including genetic differences of the patients themselves, which means that treatments are less effective if they are “one size fits all.”
However, it’s crucial to recognize that solely counting the number of approved AI-enabled medicines is a lagging indicator of success, overlooking the expanse of treatments still in development (and the long time lag due to clinical trials). We recently wrote about the “Jobs to be Done” (JTBD) for AI in enterprise healthcare.
20 Resources for Identifying New Business Opportunities Unearthing new business opportunities requires the right tools and insights, so we’ve gathered wisdom from a diverse group of professionals, including business development managers and founders.
We organize all of the trending information in your field so you don't have to. Join 24,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content